Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hodgkin Disease 41 Lymphoma 16 Urinary Bladder Neoplasms 7 Melanoma 6 Prostatic Neoplasms 3 Neoplasms 3 Leukemia 3 Glioma 3 Carcinoma, Non-Small-Cell Lung 3 Testicular Neoplasms 2 Testicular Germ Cell Tumor 2 Skin Neoplasms 2 Lymphoma, Large-Cell, Anaplastic 2 Central Nervous System Neoplasms 2 Breast Neoplasms 2 Brain Neoplasms 2 Astrocytoma 2 Urothelial Carcinoma of the Bladder 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Teratoma 1 Survival Without Progression 1 Seminoma 1 Rhabdoid Tumor 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Pathologic Complete Response 1 Oligodendroglioma 1 Neurofibromatosis 1 1

Interventions

Rituximab 259 Cyclophosphamide 238 Etoposide 114 Prednisone 97 Vincristine 96 Doxorubicin 96 Peripheral Blood Stem Cell Transplantation 95 fludarabine phosphate 87 Filgrastim 80 Cytarabine 61 Lenalidomide 60 Mycophenolic Acid 59 Melphalan 59 Radiotherapy 58 Busulfan 52 Cyclosporine 50 Carmustine 49 Whole-Body Irradiation 48 Tacrolimus 46 Methotrexate 42 Antilymphocyte Serum 38 Gemcitabine 33 Ifosfamide 32 Carboplatin 32 fludarabine 31 Dexamethasone 31 polatuzumab vedotin 29 Granulocyte Colony-Stimulating Factor 29 CT-P10 28 Methylprednisolone 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma, Large B-Cell, Diffuse × Vinblastine × Clear all

NCT01148446 2010-06-22

ANZINTER3

Fondazione Italiana Linfomi - ETS

Phase 3 Completed

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡